<DOC>
	<DOCNO>NCT01106378</DOCNO>
	<brief_summary>The purpose registry compare safety performance NEVO™ Sirolimus-eluting Coronary Stent , commercially available , CYPHER Select® Plus Sirolimus-eluting Coronary Stent complex subject present acute STEMI primary intervention , diabetes mellitus multi vessel disease . The second purpose registry evaluate safety performance NEVO™ Sirolimus-eluting Coronary Stent , commercially available CYPHER Select® Plus Sirolimus-eluting Coronary Stent complex subject diagnose acute STEMI primary intervention , diabetes mellitus and/or multi vessel disease . The data collect subject treat commercially available product follow routine clinical practice . Uniform , complete accurate data collect subject 's medical history , peri-procedurally , index hospitalization , follow-up .</brief_summary>
	<brief_title>Cynergy : CYPHER-NEVO Registry</brief_title>
	<detailed_description>The CYPHER Select® Plus Sirolimus-eluting Coronary Stent ( SES ) balloon-expandable intracoronary 316L stainless steel stent coat consists blend Sirolimus polymer . Sirolimus potent immunosuppressive agent proven prolong graft survival many animal model transplantation . Sirolimus prevent proliferation migration smooth muscle cell ( vivo vitro ) graft balloon injury model . Furthermore , Sirolimus show effective reduce restenosis need repeat revascularization demonstrate superior efficacy measure angiographic late loss binary restenosis . The NEVO™ Sirolimus-eluting Coronary Stent cobalt-chromium alloy stent platform incorporate two unique feature : reservoir technology , bioresorbable polymer prevents initial contact polymer vessel wall chronic polymer exposure . This design minimize initial tissue exposure polymer , also enable polymer resorption within approximately three month .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion criterion : Subjects treat routine clinical practice NEVO™ Sirolimuseluting Coronary Stent commercially available , CYPHER Select® Plus Sirolimuseluting Coronary Stent diagnose acute STEMI primary intervention and/or diabetes mellitus and/or multi vessel disease . Exclusion criterion : In case , index procedure , subject treat stent CYPHER Select® Plus Sirolimuseluting Coronary Stent NEVO™ Sirolimuseluting Coronary Stent mix CYPHER Select® Plus SES NEVO™ SES In case , index procedure , subject treat therapy ( e.g . balloon angioplasty , cut balloon , directional coronary atherectomy , excimer laser , rotational atherectomy , thrombectomy , etc . ) segment ultimately treat CYPHER Select® Plus SES NEVO™ SES .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>drug-eluting stent</keyword>
	<keyword>sirolimus-eluting coronary stent</keyword>
</DOC>